Drug Profile
Research programme: skin disorder therapeutics - Avecho Biotechnology
Latest Information Update: 29 Dec 2020
Price :
$50
*
At a glance
- Originator Phosphagenics
- Developer Avecho Biotechnology
- Class Steroids
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dermatitis; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dermatitis in Australia (Transdermal, Patch)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psoriasis in Australia (Transdermal, Patch)
- 07 Feb 2011 Preclinical trials in Psoriasis in Australia (Transdermal)